These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 24557498)

  • 1. Therapeutic potential of targeting glutamate receptors in Parkinson's disease.
    Finlay C; Duty S
    J Neural Transm (Vienna); 2014 Aug; 121(8):861-80. PubMed ID: 24557498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.
    Duty S
    CNS Drugs; 2012 Dec; 26(12):1017-32. PubMed ID: 23114872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.
    Litim N; Morissette M; Di Paolo T
    Neuropharmacology; 2017 Mar; 115():166-179. PubMed ID: 27055772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
    Morin N; Morissette M; Grégoire L; Di Paolo T
    Curr Neuropharmacol; 2016; 14(5):481-93. PubMed ID: 26639458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
    Bennouar KE; Uberti MA; Melon C; Bacolod MD; Jimenez HN; Cajina M; Kerkerian-Le Goff L; Doller D; Gubellini P
    Neuropharmacology; 2013 Mar; 66():158-69. PubMed ID: 22491024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease.
    Amalric M
    Curr Opin Pharmacol; 2015 Feb; 20():29-34. PubMed ID: 25462289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease.
    Brotchie JM
    Mov Disord; 1998 Nov; 13(6):871-6. PubMed ID: 9827609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamate receptors and Parkinson's disease: opportunities for intervention.
    Marino MJ; Valenti O; Conn PJ
    Drugs Aging; 2003; 20(5):377-97. PubMed ID: 12696997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset.
    Sid-Otmane L; Hamadjida A; Nuara SG; Bédard D; Gaudette F; Gourdon JC; Michaud V; Beaudry F; Panisset M; Huot P
    Eur J Pharmacol; 2020 Apr; 873():172957. PubMed ID: 32004527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamate receptors as therapeutic targets for Parkinson's disease.
    Johnson KA; Conn PJ; Niswender CM
    CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):475-91. PubMed ID: 19702565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mavoglurant as a treatment for Parkinson's disease.
    Petrov D; Pedros I; de Lemos ML; Pallàs M; Canudas AM; Lazarowski A; Beas-Zarate C; Auladell C; Folch J; Camins A
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1165-79. PubMed ID: 24960254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.
    Charvin D; Di Paolo T; Bezard E; Gregoire L; Takano A; Duvey G; Pioli E; Halldin C; Medori R; Conquet F
    Mov Disord; 2018 Oct; 33(10):1619-1631. PubMed ID: 30216534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic.
    Frouni I; Huot P
    Neurodegener Dis Manag; 2022 Aug; 12(4):203-214. PubMed ID: 35587024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
    Iderberg H; Maslava N; Thompson AD; Bubser M; Niswender CM; Hopkins CR; Lindsley CW; Conn PJ; Jones CK; Cenci MA
    Neuropharmacology; 2015 Aug; 95():121-9. PubMed ID: 25749357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
    J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
    Morin N; Morissette M; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Neuropharmacology; 2015 Dec; 99():356-68. PubMed ID: 26254863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting glutamatergic synapses in Parkinson's disease.
    Gardoni F; Di Luca M
    Curr Opin Pharmacol; 2015 Feb; 20():24-8. PubMed ID: 25462288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mGlu
    Charvin D
    Neuropharmacology; 2018 Jun; 135():308-315. PubMed ID: 29578036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.